{"url_path":"/sec/adgm/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 ****Exhibits.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/2006986/0001104659-26-059027-index.html","accession_number":"0001104659-26-059027","cik":"0002006986","ticker":"ADGM","issuer_name":"Adagio Medical Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2006986/0001104659-26-059027-index.html","primary_entity_key":"0002006986","primary_entity_name":"Adagio Medical Holdings, Inc."},"word_count":494,"has_tables":true,"body_markdown":"**Item 6.****Exhibits.**\n\nThe following exhibits are either filed or furnished with, or incorporated by reference into, this Quarterly Report on Form 10-Q.\n\n​\n\n**No.**\n\n**  ​ ​ ​**\n\n**Description of Exhibit**\n\n​\n\n​\n\n​\n\n2.1\n\n​\n\n[Business Combination Agreement, dated as of February 13, 2024, by and among Aja HoldCo, Inc., ARYA Sciences Acquisition Corp IV, Aja Merger Sub 1, Aja Merger Sub 2, Inc. and Adagio Medical, Inc. (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the SEC on August 6, 2024).](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex2-1.htm)\n\n2.2\n\n​\n\n[Consent and Amendment No. 1 to the Business Combination Agreement, dated as of June 25, 2024, by and among ARYA Sciences Acquisition Corp IV and Adagio Medical, Inc. (incorporated by reference to Exhibit 2.2 to the Company’s Current Report on Form 8-K filed with the SEC on August 6, 2024).](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex2-2.htm)\n\n3.1\n\n​\n\n[Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on August 6, 2024).](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex3-1.htm)\n\n3.2\n\n​\n\n[Amended and Restated By-Laws of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed with the SEC on August 6, 2024).](https://www.sec.gov/Archives/edgar/data/2006986/000114036124035942/ef20033584_ex3-2.htm)\n\n31.1*\n\n​\n\n[Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](adgm-20260331xex31d1.htm)\n\n31.2*\n\n​\n\n[Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](adgm-20260331xex31d2.htm)\n\n32.1**\n\n​\n\n[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](adgm-20260331xex32d1.htm)\n\n32.2**\n\n​\n\n[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](adgm-20260331xex32d2.htm)\n\n101.INS*\n\n​\n\nInline XBRL Instance Document\n\n101.CAL*\n\n​\n\nInline XBRL Taxonomy Extension Calculation Linkbase Document\n\n101.SCH*\n\n​\n\nInline XBRL Taxonomy Extension Schema Document\n\n101.DEF*\n\n​\n\nInline XBRL Taxonomy Extension Definition Linkbase Document\n\n101.LAB*\n\n​\n\nInline XBRL Taxonomy Extension Labels Linkbase Document\n\n101.PRE*\n\n​\n\nInline XBRL Taxonomy Extension Presentation Linkbase Document\n\n104*\n\n​\n\nInline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set.\n\n​\n\n*Filed herewith\n\n**Furnished herewith\n\n​\n\n53\n\n[Table of Contents](#TOC)\n\n**SIGNATURES**\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n**ADAGIO MEDICAL HOLDINGS, INC.**\n\n​\n\n​\n\n​\n\nDate: May 12, 2026\n\n​\n\n/s/ Todd Usen\n\n​\n\nName:\n\nTodd Usen\n\n​\n\nTitle:\n\nChief Executive Officer (*Principal Executive Officer*)\n\n​\n\n​\n\n​\n\nDate: May 12, 2026\n\n​\n\n/s/ Deborah Kaster\n\n​\n\nName:\n\nDeborah Kaster\n\n​\n\nTitle:\n\nChief Financial Officer and Chief Business Officer (*Principal Financial and Accounting Officer*)\n\n​\n\n​\n\n​\n\n54"}